drugset / Trial / NCT05027802

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

NCT05027802 ↗

Phase 3 Completed 61 enrolled Ipsen
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.

Timeline

Start
2022-03-14
Primary completion
2024-11-30
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Palovarotene Small molecule 5 mg Oral
Subject Palovarotene Small molecule 10 mg Oral